Potassium Bitartrate

Summary

Potassium Bitartrate (CHEMBL2105248) is an approved small-molecule antimicrobial agent (ATC A12BA03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A12BA03
• Chemistry: 188.18 Da · C4H5KO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105248
Name	Potassium Bitartrate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23681127
ChEBI	CHEBI:32034
ATC	A12BA03
Molecular formula	C4H5KO6
Molecular weight	188.18
InChIKey	KYKNRZGSIGMXFH-ZVGUSBNCSA-M

SMILES: [C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[K+]

IUPAC name: potassium (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate

ChEBI definition: An organic potassium salt of L-tartaric acid. It is a by-product of winemaking and occurs naturally in grapes, the major fruit used to produce wine.

Pharmacological roles (ChEBI): laxative, antimicrobial agent, raising agent.

Other ChEBI roles (chemical / environmental): food anticaking agent, plant metabolite, food acidity regulator, food humectant, food stabiliser.

Also known as: Acid potassium tartrate, E-336(I), Faecla, Faecula, INS NO.336(I), INS-336(I), Monopotassium tartrate (336(i)), NSC-155080, Potassium acid tartrate, Potassium bitartrate, Potassium bitartrate component of phexxi, Potassium hydrogen tartrate

Patent coverage: 29 distinct patent families (40 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).